Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21260777 | 0.91 | ESR1 (0.49) | ESR1HSD17B1HSD17B2MAOBMAPT | |
| SCHEMBL21260919 | 0.90 | ESR1 (0.48) | ESR1HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL21261042 | 0.89 | ESR1 (0.46) | ESR1 | |
| SCHEMBL21260892 | 0.89 | ESR1 (0.47) | ESR1HSD17B1 | |
| SCHEMBL21260964 | 0.88 | ESR1 (0.48) | ESR1 | |
| SCHEMBL21261000 | 0.86 | ESR1 (0.57) | ESR1 | |
| SCHEMBL21260835 | 0.85 | ESR1 (0.52) | ESR1HSD17B1 | |
| SCHEMBL21261034 | 0.84 | ESR1 (0.61) | ESR1 | |
| SCHEMBL21260895 | 0.84 | ESR1 (0.56) | ESR1 | |
| SCHEMBL21261061 | 0.84 | ESR1 (0.65) | ESR1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703747-B2 | Benzothiophene-based selective mixed estrogen receptor downregulators | The Board of Directors of the University of Illinois (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190248780-A1 | BENZOTHIOPHENE-BASED SELECTIVE MIXED ESTROGEN RECEPTOR DOWNREGULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLNOIS (US) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248780-A1 | BENZOTHIOPHENE-BASED SELECTIVE MIXED ESTROGEN RECEPTOR DOWNREGULATORS | ESR1, ESR2, GPER1 | ESR1 1/4885HSD17B1 53/4885HSD17B2 42/4885 |
| US-10703747-B2 | Benzothiophene-based selective mixed estrogen receptor downregulators | ESR1, ESR2, GPER1 | ESR1 1/4885HSD17B1 53/4885HSD17B2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.